Intervention Strategies using Agada (AyurvedicAntitoxic Formulations) for Diseases caused byEndocrine Disruptors

Introduction: Chemicals consumed through food, water, air, and personal care products disrupt our endocrine system, contributing to a range of life-threatening diseases. Since this toxicity is cumulative, it is essential to incorporate the principles of toxicity treatment. The review was conducted to evaluate the potential utility of Agada formulations in managing diseases associated with endocrine-disrupting chemicals. Methods: Electronic searches were performed using terms “Agada,” “Ayurveda,” “antitoxic,” “visha,” “dūṣhivīṣha,” “endocrine-disrupting chemicals,” and “toxicity,” including animal, clinical, or pharmacological studies of Agada formulations in any toxicant or cumulative toxin model; or conceptual reviews linking Agada to environmental/chemical toxicity. By reviewing Ayurvedic literature, studying research on Agada, and correlating the principles of treatment of dushivisha, this article examines the potential of Ayurvedic treatment for diseases induced by endocrine disruptors Results: The conceptual framework of Dūṣhivīṣha provides a strong philosophical parallel to chronic low-dose EDC exposure, legitimizing research interest. Several formulations exhibit general antitoxic effects in chemical or drug toxicity models primarily mediated by antioxidant and anti-inflammatory mechanisms. Discussion: Agada formulations may offer an integrative approach to mitigating EDC-related diseases. Their known pharmacological actions, such as antioxidant activity, free radical scavenging, Nrf2 upregulation, NF-κB inhibition, and adaptogenic effects, align with the major pathophysiological pathways triggered by EDCs. However, the current evidence base is limited by the absence of standardized formulations, inconsistent dosing, lack of endocrine biomarker assessment, and a scarcity of clinical trials. Conclusion: By applying the treatment principles of Garavisha (swallowed poison) and Dushivisha (latent poison), disorders resulting from endocrine disruptors can be effectively addressed using Agada, which directs empirical evidence through clinical trials.